PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Symptoms and signs • Pathophysiology • Risk factors • Diagnosis • Treatment • Epidemiology • Economic burden PART 06: Pipeline analysis • Pipeline information of NASH • Clinical trials for NASH PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by dosage form • Solid • Liquid PART 09: Market segmentation by route of administration • Oral • Parenteral PART 10: Geographical segmentation • Global NASH drugs market by geographical segmentation 2015-2020 • NASH drugs market in Americas • NASH drugs market in US • NASH drugs market in EMEA • NASH drugs market in APAC PART 11: Market drivers • Increase in sedentary lifestyle • Prevalence of associated health conditions • Promising pipeline • Significant unmet medical needs PART 12: Impact of drivers PART 13: Market challenges • Limited understanding of disease pathophysiology • Insufficient diagnostic technology for NASH • Stringent regulatory procedure • Adverse effects of drugs PART 14: Impact of drivers and challenges PART 15: Market trends • Rise in public awareness • Increase in strategic alliances • Patient assistance programs • Usage of off-label drugs PART 16: Vendor landscape • Competitive scenario • Arena Pharmaceuticals • AstraZeneca • F Hoffmann-La Roche • GSK • Novo Nordisk • Vivus • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Conditions associated with NASH Exhibit 03: Diagnosis of NASH Exhibit 04: Global NASH drugs market: Pipeline portfolio Exhibit 05: Clinical trials for NASH by development phase Exhibit 06: Clinical trials for NASH by trial status Exhibit 07: Global NASH drugs market 2015-2020 ($ millions) Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global NASH drugs market by dosage form Exhibit 10: Segmentation of global NASH drugs market by route of administration Exhibit 11: Global NASH drugs market by geographical segmentation 2015 Exhibit 12: Global NASH drugs market revenue by geography 2015-2020 ($ millions) Exhibit 13: NASH drugs market in Americas 2015-2020 ($ millions) Exhibit 14: NASH market in US 2015-2020 ($ millions) Exhibit 15: NASH drugs market in EMEA 2015-2020 ($ millions) Exhibit 16: NASH drugs market in APAC 2015-2020 ($ millions) Exhibit 17: Impact of drivers Exhibit 18: Impact of drivers and challenges Exhibit 19: Arena Pharmaceuticals: YoY revenue of Belviq 2013-2014 ($ millions) Exhibit 20: Arena Pharmaceuticals: Key takeaways Exhibit 21: AstraZeneca: Cardiovascular and metabolic diseases segmentation by revenue 2013 and 2014 ($ billions) Exhibit 22: Top selling products in 2014 ($ millions) Exhibit 23: AstraZeneca: YoY growth and revenue of Bydureon 2012-2014 ($ millions) Exhibit 24: AstraZeneca: YoY growth and revenue of Byetta 2012-2014 ($ millions) Exhibit 25: AstraZeneca: YoY growth and revenue of Onglyza/ Komboglyze/ Komboglyze XR 2012-2014 ($ millions) Exhibit 26: AstraZeneca: Key takeaways Exhibit 27: Roche: Key takeaways Exhibit 28: GSK: Key takeaways Exhibit 29: Novo Nordisk: Business segmentation by revenue 2014 Exhibit 30: Novo Nordisk: R&D expenditure 2014 Exhibit 31: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2012-2014 ($ millions) Exhibit 32: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2012-2014 ($ millions) Exhibit 33: Novo Nordisk: YoY growth and revenue of Prandin 2012-2014 ($ millions) Exhibit 34: Novo Nordisk: Key takeaways Exhibit 35: Vivus: YoY growth and revenue of Qsymia 2012-2014 ($ millions) Exhibit 36: Vivus: Key takeaways

Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, Viking Therapeutics.